Researchers at UCLA Health have surgically implanted blind patients with the Second Sight Orion device to improve their visual perception. The Orion device is designed to boost the ability to navigate by restoring their ability to perceive objects and movement. The device converts images captured by a tiny video camera on top of sunglasses into […]
iStar announces $44.2m Series C funding
iStar Medical said today that it completed a Series C financing round worth more than $44 million. Wavre, Belgium-based iStar plans to put the $44.2 million (€40 million) toward developing its MINIject micro-invasive glaucoma surgery (MIGS) device for sale in the U.S. and Europe. MINIject is designed to reduce intraocular pressure by enhancing aqueous humour […]
Sight Sciences raises $31m in Series D funding
Sight Sciences said today that it closed a Series D funding round of more than $30 million. The financing, led by KCK Group, totaled $31 million for the Menlo Park, Calif.-based company that specializes in devices for micro-invasive glaucoma surgery (MIGS) and in treatments for dry eye disease. The company initially said it had pulled […]
FDA approves Alcon’s AcrySof IQ PanOptix trifocal IOL
Alcon (NYSE:ALC) said today that it won FDA approval for its AcrySof IQ PanOptix trifocal intraocular lens and is preparing an initial commercial launch for the device. The Fort Worth, Texas-based company’s AcrySof IQ PanOptix device is the first and only trifocal device in the U.S. for patients undergoing cataract surgery. It’s designed to provide […]
On mixed Q2 results, Glaukos announces Avedro buy
Glaukos (NYSE:GKOS) posted its second-quarter financial results this week and reported that it plans to acquire Avedro in an effort to build out its corneal health franchise. Avedro develops single-use drug formulations designed to strengthen corneal tissue and stop the progression of a degenerative corneal ectatic disease known as keratoconus. According to the Mass.-based company, the total U.S. […]
Second Sight beat The Street in Q2 despite $8.44m loss
Second Sight Medical (NSDQ:EYES) posted second-quarter results yesterday that beat both the sales and earnings forecasts on Wall Street as it accelerated its pivot toward manufacturing a new cortical implant. Citing the costs of reorganization, the Sylmar, Calif.-based company reported a loss of $8.44 million, or -0.07¢ per share, on sales of $1.28 million for […]
Ocular Therapeutix’s ophthalmic device gains Medicare coverage early
Ocular Therapeutix (NSDQ:OCUL) said today that the Centers for Medicare and Medicaid Services has assigned a specific and permanent reimbursement J-code for its Dextenza ophthalmic insert, which is approved for the treatment of ocular inflammation and pain following ophthalmic surgery. The code assigned to Dextenza through the Healthcare Common Procedure Coding System will become effective on […]
NovaBay raises $2.4m
NovaBay Pharmaceuticals (NYSE:NBY) said this week that it raised $2.4 million in an offering that included three investors. The Emeryville, Calif.-based company has developed products for the eye care market, including a prescription for managing hygiene of the eyelids and lashes. Get the full story at our sister site, Drug Delivery Business News.
Ocular Therapeutix gains second indication for drug-delivery eye insert
Ocular Therapeutix (NSDQ:OCUL) said today that the FDA has approved a supplemental NDA for its dexamethasone ocular insert, Dextenza. The Bedford, Mass.-based company requested in January that the U.S. regulatory agency expand the current indication for Dextenza to include the treatment of ocular inflammation following eye surgery. Dextenza is designed to deliver drugs for up to 30 days […]
Glaukos touts 5-year study of glaucoma stents
Glaukos (NYSE:GKOS) said today that a study of its iStent trabecular micro-bypass stents reduced eye pressure in glaucoma patients five years after implant. The same study showed that significantly fewer iStent patients needed add-on medications after five years, the company said. The study showed that newly diagnosed, primary open-angle glaucoma (POAG) patients who received two […]
Novartis completes spinout of Alcon eye biz
Novartis (NYSE:NVS) closed the spinout of its Alcon vision care business, setting the stage for its shares to begin trading today in Switzerland and New York. The spinout, announced last June, saw each Novartis shareholder receive a single ALC share for every five NVS shares as of the close of business April 1, Novartis said last […]
MassDevice Network
@MassDevice
LinkedIn
YouTube